US HB7537 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Republican 1-0)
Status: Introduced on July 9 2020 - 25% progression, died in committee
Action: 2020-07-09 - Referred to the House Committee on Ways and Means.
Pending: House Ways And Means Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on July 9 2020 - 25% progression, died in committee
Action: 2020-07-09 - Referred to the House Committee on Ways and Means.
Pending: House Ways And Means Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in specified medical research small business pass-thru entities.
Title
Infectious Disease Therapies Research and Innovation Act of 2020
Sponsors
| Rep. Mike Kelly [R-PA] |
History
| Date | Chamber | Action |
|---|---|---|
| 2020-07-09 | House | Referred to the House Committee on Ways and Means. |
| 2020-07-09 | House | Referred to the Subcommittee on Health. |
| 2020-07-09 | House | Introduced in House |
Same As/Similar To
HB14 (Related) 2020-11-02 - Referred to the Subcommittee on Railroads, Pipelines, and Hazardous Materials.
Subjects
Accounting and auditing
Advanced technology and technological innovations
Business investment and capital
Income tax credits
Infectious and parasitic diseases
Medical research
Small business
Tax administration and collection, taxpayers
Taxation
Advanced technology and technological innovations
Business investment and capital
Income tax credits
Infectious and parasitic diseases
Medical research
Small business
Tax administration and collection, taxpayers
Taxation
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/116th-congress/house-bill/7537/all-info |
| Text | https://www.congress.gov/116/bills/hr7537/BILLS-116hr7537ih.pdf |
